Assessing the prevalence of Long COVID-19 in the Canary Islands

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to evaluate the prevalence of Long COVID-19 among individuals who have tested positive for COVID-19 in the Canary Islands. It will involve a cross-sectional descriptive approach, where patients experiencing symptoms for at least 12 weeks post-infection will undergo physical-functional evaluations conducted by trained physiotherapists. The study will utilize both self-completed questionnaires and assessments by evaluators to gather comprehensive data on the impact of Long COVID on patients' daily lives. Statistical analysis will be performed using IBM SPSS software to summarize and interpret the findings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have been positive for COVID-19 since the declaration of the state of alarm throughout the Spanish territory to deal with the health emergency situation caused by COVID-19 (March 14, 2020).
* Symptoms associated with COVID-19 at least after 12 weeks of its detection.
* Adequate cognitive and physical level to understand and perform the tests evaluation.

Exclusion Criteria:

* Present comorbidities prior to suffering from COVID-19 whose symptoms are resemble Post-acute COVID-19.
* Fibromyalgia.
* Chronic fatigue.
* Neuromuscular disease.
* Not having signed the informed consent.
* Person undergoing treatment for active cancer.

Where it's running

• University of Las Palmas de Gran Canaria
  Las Palmas de Gran Canaria, Las Palmas, Spain Recruiting

Study contacts

• Principal investigator: Aníbal Báez Suárez, PhD — University of Las Palmas de Gran Canaria
• Study coordinator: Aníbal Báez Suárez, PhD
• Email: anibal.baez@ulpgc.es
• Phone: +34652077692

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Omicron-based COVID-19 vaccine with Matrix-M given as a single dose in older adults and high-risk individuals

  A single-dose Omicron-subvariant vaccine with Matrix-M is tested to see if it is safe and can induce an immune response in adults 65+ and in younger adults with conditions that raise the risk of severe COVID-19, who were previously vaccinated.

  Recruiting at 20 sites Phase 4 Sanofi · Fair Oaks, California and 19 other locations · NCT07861542

• Secutrelvir for nonhospitalized COVID-19 in teens and adults

  This study tests whether secutrelvir can help nonhospitalized people with COVID-19 see faster symptom relief compared with a placebo.

  Recruiting Phase 3 Shionogi Inc. · Multiple Locations · NCT07746544

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• COVID-19 Registry at San Matteo (SMACORE) - patient-matching observational registry

  This registry tests how COVID-19 patients are being treated and progress across San Matteo in Pavia to understand patterns and outcomes.

  Recruiting Fondazione IRCCS Policlinico San Matteo di Pavia · Pavia · NCT07597876

• MDX2301 in healthy adults and adults at higher risk for severe COVID-19

  This study will try single and repeat doses of MDX2301 given by IV, IM, or SC to see if they are safe and trigger neutralizing activity in healthy adults and adults at higher risk for severe COVID-19.

  Recruiting at 2 sites Phase 1 ModeX Therapeutics, An OPKO Health Company · Las Vegas, Nevada and 1 other locations · NCT07445971

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.